S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:FREQ

Frequency Therapeutics (FREQ) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.28
$0.32
50-Day Range
$0.22
$14.98
52-Week Range
$0.18
$16.00
Volume
309,164 shs
Average Volume
822,537 shs
Market Capitalization
$10.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FREQ stock logo

About Frequency Therapeutics Stock (NASDAQ:FREQ)

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

FREQ Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Health calendar for March 5, 2024
See More Headlines
Receive FREQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FREQ
Fax
N/A
Employees
46
Year Founded
N/A

Profitability

Net Income
$-81,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.07 million
Book Value
$1.96 per share

Miscellaneous

Free Float
30,385,000
Market Cap
$10.94 million
Optionable
Not Optionable
Beta
0.84
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. David L. Lucchino (Age 53)
    Co-Founder, President, CEO & Director
    Comp: $1.02M
  • Mr. Richard J. Mitrano (Age 52)
    Vice President of Finance & Operations
  • Mr. James P. Abely
    Associate General Counsel & Secretary
  • Dr. John L. LaMattina Ph.D. (Age 73)
    Senior Advisor & Member of PCA Regenerative Medicine Advisory Board

FREQ Stock Analysis - Frequently Asked Questions

Should I buy or sell Frequency Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares.
View FREQ analyst ratings
or view top-rated stocks.

How were Frequency Therapeutics' earnings last quarter?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.16.

What other stocks do shareholders of Frequency Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX).

When did Frequency Therapeutics IPO?

Frequency Therapeutics (FREQ) raised $102 million in an IPO on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Frequency Therapeutics' major shareholders?

Frequency Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carl Lebel, Christopher R Loose, David L Lucchino, Peter P Pfreundschuh, Quentin Mccubbin and Richard J Mitrano.
View institutional ownership trends
.

This page (NASDAQ:FREQ) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners